Literature DB >> 20409028

Tuberculosis, bronchiectasis and chronic airflow obstruction.

Toni S Jordan1, Elspeth M Spencer, Peter Davies.   

Abstract

Both tuberculosis and bronchiectasis carry a significant burden worldwide in terms of morbidity and mortality, as well as financial, especially in the developing world. Epidemiological data for tuberculosis are now more readily available since the World Health Organisation declared it 'a global emergency' in 1993. The global prevalence of bronchiectasis, a recognized sequel of tuberculosis, is unknown, but is by no means insignificant. The pathophysiology of chronic airflow obstruction in both of these diseases is poorly understood, but it is associated with an accelerated rate of loss in pulmonary function. This article examines the global burden of tuberculosis and bronchiectasis, and focuses on the interrelation with chronic airflow obstruction.

Entities:  

Mesh:

Year:  2010        PMID: 20409028     DOI: 10.1111/j.1440-1843.2010.01749.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  32 in total

1.  Increased risk of incident osteoporosis and osteoporotic fracture in tuberculosis patients: a population-based study in a tuberculosis-endemic area.

Authors:  Y-Y Chen; J-Y Feng; W-Y Ting; Y-F Yen; P-H Chuang; S-W Pan; V Y-F Su; W-J Su
Journal:  Osteoporos Int       Date:  2017-03-22       Impact factor: 4.507

2.  Chronic respiratory disease in adults treated for tuberculosis in Khartoum, Sudan.

Authors:  R K Osman; K Mortimer; G Bjune; A I El Sony
Journal:  Public Health Action       Date:  2016-09-21

3.  HIV Associated Chronic Obstructive Pulmonary Disease in Nigeria.

Authors:  Maxwell O Akanbi; Babafemi O Taiwo; Chad J Achenbach; Obianuju B Ozoh; Daniel O Obaseki; Halima Sule; Oche O Agbaji; Christiana O Ukoli
Journal:  J AIDS Clin Res       Date:  2015-05

4.  Burden and clinical characteristics of high grade tuberculosis destroyed lung: a nationwide study.

Authors:  Deokjae Han; Hwa Young Lee; Kyeongju Kim; Taehoon Kim; Yeon-Mok Oh; Chin Kook Rhee
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

5.  Elevated interleukin-6 and bronchiectasis as risk factors for acute exacerbation in patients with tuberculosis-destroyed lung with airflow limitation.

Authors:  Jee Youn Oh; Young Seok Lee; Kyung Hoon Min; Gyu Young Hur; Sung Yong Lee; Kyung Ho Kang; Chin Kook Rhee; Seoung Ju Park; Jae Jeong Shim
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

6.  Risk factors for chronic obstructive pulmonary disease among never-smokers in Korea.

Authors:  Seok Jeong Lee; Seo Woo Kim; Kyoung Ae Kong; Yon Ju Ryu; Jin Hwa Lee; Jung Hyun Chang
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-03-05

7.  Effect of airflow limitation on acute exacerbations in patients with destroyed lungs by tuberculosis.

Authors:  Soo Jung Kim; Jinwoo Lee; Young Sik Park; Chang-Hoon Lee; Sang-Min Lee; Jae-Joon Yim; Young Whan Kim; Sung Koo Han; Chul-Gyu Yoo
Journal:  J Korean Med Sci       Date:  2015-05-13       Impact factor: 2.153

8.  Prevalence of chronic obstructive lung disease in Korea using data from the fifth Korea national health and nutrition examination survey.

Authors:  Hwayeon Park; Se Young Jung; Kiheon Lee; Woo Kyung Bae; Keehyuck Lee; Jong-Soo Han; Sarah Kim; Seryung Choo; Jin-Mook Jeong; Hyun-Ray Kim; Hyun Jung Ro; Hansol Jeong
Journal:  Korean J Fam Med       Date:  2015-05-22

9.  Clinical characteristics and economic burden of tuberculous-destroyed lung in Korea: a National Health Insurance Service-National Sample Cohort-based study.

Authors:  Hwa Young Lee; Deok Jae Han; Kyung Joo Kim; Tae Hoon Kim; Yeon-Mok Oh; Chin Kook Rhee
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

10.  Pulmonary Impairment in Tuberculosis Survivors: The Korean National Health and Nutrition Examination Survey 2008-2012.

Authors:  Jae-Woo Jung; Jae-Chol Choi; Jong-Wook Shin; Jae-Yeol Kim; Byoung-Whui Choi; In-Won Park
Journal:  PLoS One       Date:  2015-10-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.